Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia [1]

Clinical Chemistry

Volumn 50, Issue 9, 2004, Pages 1702-1703

  Hertig, Alexandre ^a   Berkane, Nadia ^a   Lefevre, Guillaume ^a   Toumi, Karine ^a   Marti, Hans Peter ^a   Capeau, Jacqueline ^a   Uzan, Serge ^a   Rondeau, Eric ^a  

^a HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN RECEPTOR 1;

GENE EXPRESSION; GESTATION PERIOD; HUMAN; HYPERTENSION; LETTER; MATERNAL HYPERTENSION; MATERNAL SERUM; PREECLAMPSIA; TROPHOBLASTIC DISEASE;

EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; HYPERTENSION; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; SENSITIVITY AND SPECIFICITY;

EID: 4344564076     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2004.036715     Document Type: Letter

References (4)

1. Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet 2001;357: 53-6.
2. Maynard SE, Min J-Y, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111:649-58.
3. Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003;278:12605-8.
4. Richard JL, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-83.